Miao Xu
Nankai University(CN)National Medical Products Administration(CN)National Health and Family Planning Commission(CN)China Banking Regulatory Commission(CN)Guangzhou Experimental Station(CN)National Institutes for Food and Drug Control(CN)National Center for Advancing Translational Sciences(US)
Publications by Year
Research Areas
SARS-CoV-2 and COVID-19 Research, Tuberculosis Research and Epidemiology, COVID-19 Clinical Research Studies, Viral Infections and Immunology Research, Mycobacterium research and diagnosis
Most-Cited Works
- → Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial(2020)1,207 cited
- → Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2(2020)797 cited
- → Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2(2020)795 cited
- → Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial(2021)574 cited
- → Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay(2020)464 cited
- → Impact of the Delta variant on vaccine efficacy and response strategies(2021)234 cited